Contribution of fluorodeoxyglucose positron-emission tomography combined with magnetic resonance imaging for differential diagnosis between radionecrosis and recurrence of treated brain metastasis

This is the authors' abstract. We don't add key points for this paper.

Purpose Differentiating between changes after radiotherapy and radionecrosis during the follow-up of brain metastasis remains challenging. Hybrid positron-emission tomography/magnetic resonance imaging is a relatively novel imaging modality that integrates advanced magnetic resonance imaging sequences with metabolic data from positron-emission tomography. This study ailed to evaluate retrospectively the contribution of hybrid ( 18 F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging in distinguishing radionecrosis from recurrent cerebral metastatis, comparing the diagnosis performance of ( 18 F)-fluorodeoxyglucose positron-emission tomography and magnetic resonance imaging independently, without relying clinical or prior imaging data. Patients and methods Over a one-year period, we included 72 patients with brain metastases undergoing evaluation for differential diagnosis between recurrence and radionecrosis. Two senior nuclear medicine physicians and two senior radiologists independently analysed positron-emission tomography and magnetic resonance images. For semi-quantitative positron-emission tomography, analysis maximum standardized uptake value was measured at 30 min and 4 h postinjection and retention indices were calculated. Reading correlations between physicians was assessed using Cohen's Kappa coefficients. Clinical and imaging follow-up, considered the gold standard, was used to classify the lesion. For discordant cases, a joint interdisciplinary reading was conducted. Results A total of 142 treated brain metastases from 90 hybrid ( 18 F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging scans of 72 patients were analysed. Based on the gold standard for diagnosis, the 142 lesions were categorized into two groups: 47 recurrences and 95 cases of radionecrosis. The sensibility and sensitivity of hybrid ( 18 F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging were 97.9 and 100 %, respectively, outperforming both magnetic resonance imaging and positron-emission tomography alone. Discussion Dual time-point ( 18 F)-fluorodeoxyglucose positron-emission tomography, with retention index calculation, shows significant in differentiating radionecrosis from recurrence. Technological advancements, such as hybrid positron-emission tomography/magnetic resonance imaging, enhance diagnostic accuracy in substantial patients’ cohorts. Further studies incorporating histological confirmation as the gold standard is warranted to validate these findings.